Physician profile
Gautam K Samadder
NPI 1033231188
$52,870.65
in general payments reported to CMS, 2019-2025
29 companies · $18K in 2025
The $18K reported for 2025 was more than what 96% of Sleep Medicine (Internal Medicine) providers received nationally (typical 2025 total: $447).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $773 · 2020: $891 · 2021: $5,593 · 2022: $5,001 · 2023: $20K · 2024: $2,228 · 2025: $18K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $30K · Food and Beverage: $8,010 · Travel and Lodging: $1,971 · Consulting Fee: $820 · Education: $42.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $29,770.00 |
| Food and Beverage | $8,009.91 |
| Travel and Lodging | $1,970.73 |
| Consulting Fee | $820.00 |
| Education | $42.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $15,060.49 | 2019-2025 | |
| Lilly USA, LLC | $14,480.59 | 2025 | Zepbound |
| Idorsia Pharmaceuticals US INC | $8,920.63 | 2023 | Quviviq |
| Inspire Medical Systems, INC. | $5,151.67 | 2019-2025 | Inspire |
| Harmony Biosciences LLC | $4,633.96 | 2020-2025 | Wakix |
| Avadel Cns Pharmaceuticals, LLC | $2,112.59 | 2023-2025 | Lumryz |
| Zoll Respicardia, INC. | $513.30 | 2020-2023 | Remede System |
| Astrazeneca Pharmaceuticals Lp | $354.92 | 2020-2025 | Breztri, Airsupra |
| Eisai INC. | $296.29 | 2020-2022 | |
| Axsome Therapeutics, INC. | $262.58 | 2023-2025 | Sunosi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $199.94 | 2019-2023 | Xifaxan |
| Teva Pharmaceuticals USA, INC. | $128.83 | 2023 | Uzedy |
| Esperion Therapeutics, INC. | $101.34 | 2021 | |
| Glaxosmithkline, LLC. | $93.12 | 2020-2023 | Trelegy Ellipta |
| Merck Sharp & Dohme LLC | $91.62 | 2021-2023 | Belsomra |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironwood Pharmaceuticals, INC | $77.86 | 2020-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $68.63 | 2019-2024 | Spiriva Respimat |
| Janssen Biotech, INC. | $45.07 | 2019-2023 | Stelara |
| Arbor Pharmaceuticals, INC. | $40.82 | 2019-2021 | |
| Redhill Biopharma INC. | $38.53 | 2021 | |
| Currax Pharmaceuticals LLC | $29.73 | 2019 | |
| Medicomp INC | $26.41 | 2023 | Telepatch Cardiac Monitor |
| 3b Medical, INC. | $24.36 | 2025 | Luna |
| Fisher & Paykel Healthcare INC | $22.49 | 2025 | Fisher & Paykel Healthcare |
| Verona Pharma, INC. | $22.21 | 2025 | Ohtuvayre |
| Inogen, INC. | $20.66 | 2025 | |
| Qol Medical, LLC | $19.63 | 2022 | |
| Ardelyx, INC. | $19.63 | 2022 | |
| Abbvie INC. | $12.75 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gautam Samadder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.